Aster DM Healthcare Limited has informed the Exchange about Competition Commission of India approval

Listed Co AcquisitionStrategic Transactions View source PDF Explain this filing

ASTERDM · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

+1.5%Reaction day

₹491.50

prior close

₹498.00

announcement price

After-mkt

timing

Nifty Smallcap 250market · index membership as recorded later (tracked since Jun 2026)+0.9%+0.6% vs market

Hospital peers, median of 20sector+0.5%+1.0% vs sector

On the reaction day the stock moved 0.6 pts more than Nifty Smallcap 250 and 1.0 pts more than its Hospital peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

-0.8

10m

+0.1

15m

+0.1

30m

-0.4

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

+1.5+0.9+0.6+0.5+1.0

Next day

+1.4+1.4-0.0+0.0+1.4

+2.1+3.4-1.2+1.6+0.5

+3.8+4.2-0.4+1.8+1.9

+3.0+4.5-1.5+1.0+2.0

+4.2+4.4-0.3+0.1+4.1

+4.5+2.4+2.1+1.4+3.1

15d

+8.0-1.0+9.1-6.7+14.8

+19.6+7.7+12.0+1.1+18.6

+18.8+13.5+5.3+0.5+18.4

+22.1+18.0+4.1+6.6+15.5

UpDownMarket · Nifty Smallcap 250Sector · Hospital peers, median of 20Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Aster DM Healthcare has received approval from the Competition Commission of India (CCI) on April 15, 2025 for its proposed acquisition and merger with Quality Care India Limited (QCIL). The transaction involves acquiring 1.90 crore equity shares of QCIL from BCP Asia II TopCo IV Pte. Ltd and Centella Mauritius Holdings Limited, through a share swap of 1.86 crore Aster DM equity shares issued on a preferential basis. Additionally, a scheme of amalgamation has been proposed for QCIL to merge into Aster DM Healthcare. This is a key regulatory milestone; the detailed CCI order is still awaited, and other approvals (including shareholder and NCLT) are still pending.

Likely market impact

This is a positive step forward for the previously announced QCIL acquisition and merger, removing a major regulatory hurdle. Shareholders should watch for the share exchange ratio, NCLT and shareholder approvals, and any potential dilution from the preferential share issuance.